Mometasone furoate prescribing across the NHS.
This line is 97% nasal spray: mometasone is England's hay fever and rhinitis steroid, 3m items a year for £14m, peaking reliably every early summer. Generic pricing has made it the default steroid spray, and the seasonality in its chart is among the cleanest on the site.
The NHS in England dispensed 2,955,093 prescription items of Mometasone furoate in the 12 months to July 2026, across primary care and hospitals.
Spending on Mometasone furoate over those 12 months was £11.4m at net ingredient cost, the list price of what was dispensed before any discounts.
Items were up 0.5% on the previous 12 months.
100% of Mometasone furoate volume moved through primary care and 0% through hospital pharmacies.
Mometasone furoate is the largest of 9 chemical substances in Drugs used in nasal allergy (BNF 12.2.1), by items dispensed.
Among Integrated Care Boards, NHS Cheshire and Merseyside ICB dispensed the highest volume of Mometasone furoate.
Source: NHS Business Services Authority open data (English Prescribing Data and SCMD), OGL v3.0. Items count prescriptions dispensed, not patients treated.
Diamond markers show events around this period: NICE decisions, safety alerts, supply notices, Drug Tariff moves and price concessions, new suppliers in dm+d and framework awards. Hover a marker for the date and type. The evidence behind each one, with the source quote and link, sits behind Apply.
| Month | Items | Spend (NIC) |
|---|---|---|
| July 2026 | 256,612 | £736k |
| June 2026 | 269,161 | £836k |
| May 2026 | 250,837 | £780k |
| April 2026 | 262,528 | £819k |
| March 2026 | 265,747 | £974k |
| February 2026 | 232,427 | £856k |
| January 2026 | 252,395 | £926k |
| December 2025 | 246,578 | £1.1m |
| November 2025 | 224,088 | £1.0m |
| October 2025 | 244,613 | £1.1m |
| September 2025 | 232,812 | £1.2m |
| August 2025 | 217,295 | £1.1m |
The same series as the chart, most recent month first. The full monthly history, as CSV, sits behind Apply.
35.7% of its class.
Mometasone furoate is the largest of 9 chemical substances in Drugs used in nasal allergy (BNF 12.2.1), by items dispensed in July 2026. The full class league, who's gaining, and the month-by-month share movement sit behind Apply.
Average items by calendar month across the full history, indexed to the annual mean.
Pharmacies also supplied 88,339 items under Pharmacy First in the twelve months to July 2026. They are not in the prescribing figures on this page, because no GP prescribed them. Source: NHSBSA Prescription Cost Analysis, OGL v3.0.
Mometasone furoate across all 36 ICBs.
Every Integrated Care Board in England, shaded by how much mometasone furoate its GPs dispense per head of population. Hover an ICB to name it. The ranked figures for all 36 ICBs, and the drill-down to practice level, are in the full report.
Darker shading marks where Mometasone furoate is dispensed most per head of population. Exact figures for every ICB, and the drill-down to practice level, are in the full report.
Zoomed out to the 7 NHS regions.
The same 12 months rolled up to NHS England's seven regions, ranked by intensity.
The teaser view.
Three rows each. The full 36-ICB view, every prescribing organisation, every strength and the hospital picture sit below the fold, behind Apply.
- 1 NHS Cheshire and Merseyside ICB 182k
- 2 NHS North East and North Cumbria ICB 179k
- 3 NHS West and North London ICB 171k
- – + 33 more. See the full 36-ICB table. See all →
- 1 NHS Derby and Derbyshire ICB +5.7%
- 2 NHS Lancashire and South Cumbria ICB +3.1%
- 3 NHS Thames Valley ICB +3.0%
- – + 33 more. See every ICB, ranked. See all →
- 1 Mometasone 50micrograms/dose nasal spray 98%
- 2 Nasonex 50micrograms/dose nasal spray 2%
- 3 Clarinaze Allergy Control 0.05% nasal spray 0%
- – + 0 more. See every strength and pack. See all →
Split of items across NHSBSA primary care and SCMD hospital dispensing.
Prescribing by deprivation.
Items per 1,000 registered patients by deprivation decile (1 = most deprived), practice deprivation weighted by where each practice's patients live. Read the shape rather than the absolute level: the most and least deprived deciles cover far fewer practices, and age structure drives much of the gradient.
The devolved nations.
| Nation | Items · 12 months | Data to |
|---|---|---|
| England | 3.0m | July 2026 |
| Scotland | 348k | June 2026 |
| Northern Ireland | 73k | May 2026 |
| Wales | 188k | April 2026 |
Each nation publishes its own community prescribing data, with different coding and list rules, so read these per-nation rather than as an exact UK total. Sources: NHSBSA (England), Public Health Scotland, NHS Wales Shared Services Partnership, OpenDataNI. Used under the Open Government Licence v3.0.
What open data won't tell you about mometasone furoate.
Skin preparations of the same molecule sit under a different chemical code, so this page is the nose's market alone, and OTC steroid sprays compete with every item of it.
Asked and answered.
Is mometasone furoate prescribing rising or falling in the NHS?
Rising. England dispensed 2,955,093 items of Mometasone furoate in the 12 months to July 2026, up 0.5% on the previous 12 months. Items count prescriptions dispensed, not patients treated, so the change can reflect dose and duration shifts as well as patient numbers.
How much does the NHS spend on mometasone furoate?
£11.4m at net ingredient cost in the 12 months to July 2026. Net ingredient cost is the list price of the medicine before discounts and rebates; the NHS's final bill, especially for hospital medicines, is usually lower.
Where in England is mometasone furoate prescribed most?
By raw volume, NHS Cheshire and Merseyside ICB dispensed the most mometasone furoate in the last 12 months. Raw volume favours the biggest populations; the map on this page shades every ICB by items per head to correct for that.
How up to date is this data?
This page runs to July 2026, the most recent NHSBSA release. Prescribing data publishes roughly six to eight weeks in arrears, and DoseTrend refreshes within 48 hours of each monthly release.
The full breakdown.
Every ICB, every prescribing organisation, every strength, the hospital view with what trusts paid and who holds each framework line, Signals with their sources, and the monthly briefing PDF. The rows below are placeholders; the real tables sit behind the application.
Track mometasone furoate like this, every month.
£1,500 a month per molecule. Apply and we'll pre-fill Mometasone furoate for you.